Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study.

Radiat Oncol · 2023 · PMC10259021 · PMID 37308914

Europe PMC DOI

hedged sentence

0.7550

closest p · 15.1× alpha

0.7550

boldest claim

The sentences

showed a trendP = 0.755not close (p > 0.1)

They also found that the combination of SBRT with sorafenib showed a trend toward prolonged median OS (16.6 months versus 10.9 months, P = 0.755), but no statistical difference was observed.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.